• Six abstracts; including new phase 2 data for nemolizumab across PN and AD and new real-world evidence highlighting the PN disease burden being presented
• Prurigo nodularis: Rapid onset of action with over three times greater itch reduction versus placebo within 48 hours of the first dose and a four times greater improvement in sleep versus placebo as early as Day 4

• Galderma well positioned for long-term growth in highly attractive dermatology sector

• Experienced management team and Board to build on strong Galderma foundations

• Dr. Flemming Ornskov (ex-Shire and Bayer) appointed CEO and Thomas Dittrich appointed CFO (ex-Shire and Amgen)

FORT WORTH, Texas, Mar. 25, 2022 /PRNewswire/ -- Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates.

Healthcare professionals (HCPs) encouraged to investigate true impacts beyond the visible, empower patients with knowledge and aim for ‘clear’ (IGA 0) skin to improve outcomes

• Galderma will share exciting results from the Sculptra^® Cheek Wrinkle study showing the long-lasting effectiveness and safety of Sculptra, as well as high aesthetic improvement and patient satisfaction over two years[i]  

• The company will also present 10 research poster